Mammalian Cell Fermentation Technology Market anticipated journey towards the lucrative US$ 68 Billion valuation. At a CAGR of 10% by 2034 | Future Market Insights, Inc.
23 avr. 2024 12h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, April 23, 2024 (GLOBE NEWSWIRE) -- The mammalian cell fermentation technology market is estimated to be worth US$ 45.9 billion in 2024 and is projected to be valued at US$ 68 billion by...
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
13 déc. 2023 16h30 HE
|
Certara
Combined Certara-Applied Biomath organization establishes the life sciences industry’s largest quantitative systems pharmacology center.
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
21 nov. 2023 16h30 HE
|
Certara
Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
19 sept. 2023 08h15 HE
|
Certara
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to...
Lyophilization Services for Biopharmaceuticals Market worth $3.58 Billion by 2028 - Exclusive Report by The Insight Partners
04 sept. 2023 10h08 HE
|
The Insight Partners
Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Lyophilization is a process of isolating a solid substance from a solution. It is also known as freeze-drying is a process. The process is carried by...
Certara Reports Second Quarter 2023 Financial Results
09 août 2023 16h15 HE
|
Certara
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. ...
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
13 juil. 2023 16h30 HE
|
Certara
PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of...
Certara Reports First Quarter 2023 Financial Results
08 mai 2023 16h15 HE
|
Certara
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. ...
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
27 avr. 2023 08h00 HE
|
Certara
PRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...
Mydecine Innovations Group Provides Corporate Update
03 avr. 2023 06h00 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering...